Investigations of Pathologic Remodeling Using Pediatric Heart Failure Serum

使用小儿心力衰竭血清进行病理重塑的研究

• 批准号: 10312788
• 负责人: CARMEN C SUCHAROV
• 金额: $ 10.74万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-12-01 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10312788
• 关键词: Address; Adult; Adverse effects; Age; Arrhythmia; Award; Biocompatible Materials; Bioinformatics; Biological; Biological Markers; Blood Circulation; Blood Volume; Cardiac; Cardiac Myocytes; Cause of Death; Cells; Cessation of life; Child; Childhood; Clinical; Clinical Data; Clinical Trials; Cyclic AMP; Data; Devices; Dilated Cardiomyopathy; Disease; Economic Burden; Etiology; Faculty; Failure; Fibrosis; Freedom; Functional disorder; Gene Expression; Generations; Health Care Costs; Heart; Heart failure; Home; Hospitalization; Hypertrophy; In Vitro; Infusion procedures; Investigation; Knowledge; Malignant Childhood Neoplasm; Malignant Neoplasms; Measurement; Mediating; Medical; Mentorship; Metabolic dysfunction; MicroRNAs; Milrinone; Mitochondria; Molecular; Morbidity - disease rate; Muscle Cells; Myocardial; Myocardium; Neonatal; Outcome; Pathologic; Patients; Population; Publishing; Quality of life; Rattus; Recovery; Research; Risk; Sampling; Serum; Symptoms; System; Testing; Time; Tissues; Transplant Recipients; Transplantation; United States; Ventricular; Ventricular Function; Vulnerable Populations; Work; base; cell growth regulation; circulating microRNA; clinically relevant; combinatorial; design; disability; epidemiologic data; exosome; improved; inhibitor; lipid metabolism; microvesicles; mitochondrial dysfunction; mortality; novel; novel therapeutics; patient oriented research; pediatric heart failure; preservation; prognostic value; response; therapeutic target; transcriptome; treatment response

Abstract Heart failure (HF) is one of the leading causes of hospitalization in the United States and is associated with substantial adverse effects on quality of life as well as a mortality rate on the order of the most lethal forms of cancer. Treatment for adults with HF varies from well- established neurohormonal inhibitors to device therapy. However, despite the demonstrated benefits of current therapy, the societal and economic burdens of HF are increasing. In pediatric HF from dilated cardiomyopathy (DCM) five-year freedom from death or transplant remains low, ranging from 54%-63%. This suggests that there are underlying myocardial cellular mechanisms uniquely regulated in children with HF. Irrespective of age or etiology of HF, new therapies for HF are necessary to improve morbidity and mortality and decrease health care costs. The proposed studies will use meticulously preserved pediatric serum along with all relevant clinical data, and are designed to integrate patient samples with an in vitro system that is a surrogate for pathological changes observed in the myocardium. In addition, this award will provide protected time for Dr. Sucharov to continue her successful mentorship of junior faculty and fellows trainees. The translational aspect of this work will be relevant to MD fellows and junior faculty, and will allow patient oriented research without risk to children with HF.

摘要 心力衰竭(HF)是美国住院的主要原因之一， 与对生活质量的严重不利影响以及对 这是最致命的癌症之一。成人心力衰竭的治疗方法有很大不同- 已确定的神经激素抑制物可用于设备治疗。然而，尽管展示了 当前治疗的益处，心力衰竭的社会和经济负担正在增加。在儿科 扩张型心肌病(DCM)引起的心衰五年免于死亡或移植的几率仍然很低， 从54%到63%不等。这表明存在潜在的心肌细胞 心力衰竭儿童独特的调节机制。无论年龄或病因，新的 治疗心力衰竭是必要的，以提高发病率和死亡率，减少医疗保健。 成本。 拟议的研究将使用精心保存的儿科血清以及所有相关的 临床数据，并被设计为将患者样本与体外系统集成在一起 作为观察到的心肌病变的替代物。此外，该奖项将 为苏查罗夫博士继续她对初级教员的成功指导提供有保障的时间 和研究员实习生。这项工作的翻译方面将与MD研究员和 初级教员，并将允许以患者为导向的研究，而不会对患有心力衰竭的儿童造成风险。